Here you will find valuable information and resources that can assist you. CAR T-Cell Therapy is approved for the treatment of Relapsed / Refractory B-NHL & B-ALL. India’s first indigenous CAR-T therapy, developed at IIT Bombay.
You are not alone. This page is designed to help you and your family understand CAR-T cell therapy, what to expect during treatment, and the support available to you. Always speak with your doctor to understand what is right for you.
If you’re 15 or older and have B-cell Non-Hodgkin’s Lymphoma or B-cell Acute Lymphoblastic Leukaemia, your haematologist or medical oncologist might recommend NexCAR19™ if:
NexCAR19™ is for patients with challenging B-cell cancers, which are often inadequate to treat with chemoimmunotherapy.
NexCAR19™ demonstrates strong clinical efficacy with rapid response rates, durable remissions, and a streamlined manufacturing timeline – addressing critical unmet needs in relapsed/refractory B-cell malignancies.
NexCAR19™ is a type of CAR-T cell therapy. T-cells are naturally made by your body as an advanced defense against viruses and cancer cells. As they mature, they develop specific connectors (receptors) to target key signals in cancer cells. However, cancers can escape the inbuilt defense mechanism of T-cells, which can lead to an increase in tumor burden and can result in the survival of cancer cells and a further increase in tumor burden. CD19 is a protein commonly present on the surfaces of certain B-cell cancers.
Our scientists have designed instructions for your T-cells to express unique proteins called Chimeric Antigen Receptors (CARs) on their surface, which will enable them to bind to a specific target on the cancer cells. These instructions are delivered genetically using a vehicle known as a lentiviral vector.NexCAR19 targets a marker called CD19, which is commonly present on the surface of cancerous B-cells.
Select and activate T-cells from the patient’s blood sample.
Deliver genetic instructions to T-cells using viral vectors.
Enable T-cells to express Chimeric Antigen Receptors (CARs).
Multiply CAR-T cells to achieve the therapeutic dose.
Administer CAR-T cells to the patient for targeted cancer treatment.
At the heart of ImmunoACT’s innovation is a next-generation cell and gene therapy platform, purpose-built to deliver affordable efficacy without compromising safety. Our approach blends cutting-edge science with thoughtful design to make these therapies more accessible and tolerable.
Our CAR-T constructs use fully humanized components, making them more “familiar” to the immune system. This reduces the risk of rejection, minimizes off-target toxicity, and improves patient experience by lowering the need for intensive supportive care.
Each CAR we design includes:
Our CAR-T therapies integrate humanized sequences and undergo rigorous optimization to ensure potency, persistence, and safety. By reducing the likelihood of severe toxicities, we are not just improving patient safety, we are redefining how cell therapies can be delivered.
The gene sequence of the CAR construct is first integrated into a plasmid, which is then used to produce a lentiviral vector. This vector delivers the CAR gene into T cells, enabling them to recognize and attack cancer cells.
Our strong association with over 80 leading cancer treatment hospitals in India ensures hassle-free treatment with our CAR-T cell therapies.
Disease burden: If it’s high, your doctor may plan NexCAR19 treatment alongside another therapy to reduce it first.
Timing of prior treatments: Since NexCAR19™ uses your T-cells, previous immunotherapies or chemotherapies might impact their quality or quantity. Your doctor will time the collection and treatment to ensure the best T-cells are available to fight your cancer.
The cell collection process happens at the treatment center.
It is a day-care procedure, and usually requires 4-6 hours.
It is recommended to wear loose-fitting clothing for the procedure.
ImmunoACT processes the Leukapheresis sample within 24 hours. The hospital will inform you when manufacturing is proceeding.
Your Journey to Recovery
A Step-by-Step Path Through CAR-T Cell Therapy
At the certified treatment center, you will meet with your team and get assessed to see if you are eligible for NexCAR19.
White blood cells are collected through apheresis, a process similar to blood donation.
After collecting your blood cells, NexCAR19™ is usually manufactured around 15 days.
In the Interim period, your physician may administer a Bridging Therapy to lower your disease burden.
~5 days before NexCAR19™’s infusion, you will start receiving a Conditioning Chemotherapy so that your body is ready for NexCAR19™’s infusion.
NexCAR19™ may cause side effects that are severe and/or life-threatening. Call/visit your physician or get emergency help right away if you get any of the following
Before receiving NexCAR19™, inform your physician about any medical issues, including if you have or have had
Neurologic problems (such as seizures, stroke, or memory loss).
Lung or breathing problems.
Heart problems.
Liver problems.
Kidney problems.
A recent or active infection.
Inform your physician about all the medications you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. Inform your physician if you are pregnant, planning to be pregnant, or breastfeeding.
A pregnancy test may be then performed prior to your starting treatment. No information is available of NexCAR19 use in pregnant or breastfeeding women, hence, its use is not recommended in cases of pregnancy.
Caregivers play a vital role in CAR T treatment, providing essential support throughout the patient’s recovery. CAR T patients require a full-time caregiver to:
Your loved one’s journey with B-cell cancer is filled with challenges. Being prepared for each step of this treatment will smoothen the care process.
Essential information guide for NexCAR19™ (Acetalycabtagene autoleucel), a CAR-T cell therapy for treating relapsed/refractory B-cell lymphomas and B-cell acute lymphoblastic leukemia.